AVAVA MIRIA General Use

A general protocol to treat a variety of dermatologic conditions and collect patient feedback.

Primary outcome is the collection and analysis of patient questionnaires related to the overall experience of the device treatment. Secondary outcome measures include physician and subject evaluations in regards to improvement seen in the device as well as assessment of side effects.

Study Overview

• Status: Recruiting
• Conditions: Acne Scars - Mixed Atrophic and Hypertrophic; Scars; Acne; Wrinkle; Skin Texture Disorder; Pigment; Lesion
• Intervention / Treatment: Device: AVAVA

• Study Type: Interventional
• Enrollment (Estimated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Alexander Denis; Phone Number: 6176936669; Email: studies@avavaskin.com

Study Locations

• United States
  • Massachusetts
    • Waltham, Massachusetts, United States, 02451
      • Recruiting
      • AVAVA, Inc.
      • Contact: Alexander Denis; Phone Number: 617-693-6669; Email: adenis@avavaskin.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male or female subjects between 18 to 70 years of age.

2. Dermatologic condition that can be addressed by the laser, including but not limited to:

   1. Wrinkles
   2. Scars
   3. Acne Scars
   4. Active Acne
   5. Dyschromia
   6. Cutaneous Lesions such as Age or Sun Spots
   7. Melasma
   8. Laxity
3. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.

4. Willingness to comply with the following during the study, including the follow-up period:

   1. maintain consistent skin care regimen on treated areas.
   2. cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.
   3. refrain from using systemic corticosteroids, according to Investigator discretion.
   4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.
   5. refrain from any other procedures in the treatment areas.
5. Willingness and ability to comply with study instructions and return for required visits.
6. Subject has read and signed a written informed consent form.
7. Subject lives within 50 miles of study site.
8. Willingness to shave hair in intended treatment area

Exclusion Criteria:

1. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,
2. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)
3. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)
4. Active vitiligo, psoriasis, or eczema in the treatment area
5. Injection of dermal filler in the target areas within previous 1 month (e.g., collagen, hyaluronic acid filler)
6. Cosmetic procedures in the target areas within prior 3 months (e.g., laser, microdermabrasion, skin peel)
7. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.
8. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.
9. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.
10. Active localized or systemic infection, or an open wound in area being treated.
11. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)
12. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)
13. History of connective tissue disease, such as lupus or scleroderma.
14. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).
15. History of gold therapy.
16. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
17. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.
18. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.
19. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
20. History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications.
21. Current enrollment in a clinical study of any other unapproved investigational drug or device
22. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Subjects treated with the AVAVA Device	Device: AVAVA; 1550nm Non-Ablative Fractional Laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Completion of Post-Treatment Subject Questionnaire	Post-treatment questionnaire to evaluate the overall patient experience including descriptions of the treatment session and overall patient experience.	Immediate Post-Treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Blinded Assessment of Before and After Imaging by Trained Dermatologist	Subject images will be placed in a randomized order and blinded graders will be asked to identify the post-treatment image.	Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment
Completion of Follow-Up Subject Questionnaire	Questionnaire evaluates the subject evaluated results of the study including questions related to the device such as whether or not they would participate in additional treatments or recommend the procedure to friends/family	3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment
Physician Rated Satisfaction	Percentage of subject results that treating physician was satisfied with at end of study. Physician Rated satisfaction with included options of Very Satisfied, Satisfied, Slightly Satisfied, Neutral, Dissatisfied.	Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment
Subject Rated Satisfaction	Percentage of subjects satisfied with their results at end of study. Subject Rated satisfaction with included options of Very Satisfied, Satisfied, Slightly Satisfied, Neutral, Dissatisfied.	Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment
Physician Rated Global Clinical Aesthetic Improvement Scale Scoring	Physician will be asked to rate subject improvement on a 5 point scale. 0 - Worsened, 1-No Change, 2-Minor Improvement, 3-Moderate Improvement, 4-Significant Improvement	Baseline, 3 Months Post Final Treatment, 6 Months Post Final Treatment, 12 Months Post Final Treatment
Subject tolerance of procedure based on pain score during treatment per Visual Analogue Scale	Subjects are asked to rate their pain scores from 0 (No pain) to 10 (worst imaginable pain)	Immediate Post Treatment

Collaborators and Investigators

• Sponsor: AVAVA, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): September 11, 2024
• Primary Completion (Estimated): December 30, 2027
• Study Completion (Estimated): December 30, 2027

Study Registration Dates

• First Submitted: March 6, 2025
• First Submitted That Met QC Criteria: March 6, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 6, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Skin Diseases; Acneiform Eruptions; Sebaceous Gland Diseases; Acne Vulgaris; Hypertrophy
• Other Study ID Numbers: AV-24-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plan to share individual data with other researchers at this time.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No